{"title": "Las 8 vacunas candidatas para COVID-19 que ya se est\u00e1n probando en personas", "author": null, "url": null, "hostname": null, "description": "Las 8 vacunas candidatas para COVID-19 que ya se est\u00e1n probando en personas", "sitename": null, "date": "2020-05-21", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "El desarrollo de vacunas es una de las principales estrategias terap\u00e9uticas para hacer frente a la actual pandemia de COVID-19. En los \u00faltimos meses, numerosas instituciones p\u00fablicas y privadas han abordado el reto de obtener una vacuna para COVID-19 a trav\u00e9s de diferentes plataformas y aproximaciones. Como resultado, existen m\u00e1s de 100 vacunas candidatas para la enfermedad. La mayor parte de ellas est\u00e1n todav\u00eda en fase de investigaci\u00f3n precl\u00ednica, pero algunas de ellas ya han avanzado a fase cl\u00ednica y su eficacia y seguridad en personas est\u00e1 siendo evaluada en ensayos cl\u00ednicos.\nExisten diferentes tipos de vacunas para COVID-19. Algunas utilizan virus inactivados. Otras utilizan virus que han sido modificados para no resultar infectivos, en los que se empaquetan instrucciones gen\u00e9ticas del coronavirus. Y otras est\u00e1n basadas en ARN mensajero o ADN. En todos los casos, el objetivo es el mismo: preparar al organismo para un posible encuentro con el coronavirus SARS-CoV-2, responsable de la enfermedad. Independientemente del tipo, las vacunas proporcionan (directa o indirectamente) prote\u00ednas virales que activan al sistema inmunitario y lo entrenan para que sea capaz de detectar y eliminar al virus en el futuro.\nDado que las vacunas est\u00e1n destinadas a su utilizaci\u00f3n masiva en la poblaci\u00f3n, existen regulaciones estrictas, tanto para garantizar su eficacia y seguridad como para asegurar que su producci\u00f3n, comercializaci\u00f3n y distribuci\u00f3n se realiza en las condiciones adecuadas.\nAl igual que ocurre con otros tratamientos cl\u00ednicos, un requisito indispensable para toda vacuna es que se realicen ensayos cl\u00ednicos que demuestren su efectividad para generar inmunidad frente al agente infeccioso y su seguridad al utilizarse en humanos. Normalmente, los ensayos cl\u00ednicos transcurren en tres fases. La primera, realizada en pocas personas, est\u00e1 destinada a evaluar su seguridad y posibles efectos adversos. La segunda fase, con mayor n\u00famero de participantes, eval\u00faa la eficacia y sus resultados se confirman en la tercera, que incluye miles de participantes.\nEl pasado 15 de mayo, la Organizaci\u00f3n de la Salud public\u00f3 un\n[listado](https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines) de las vacunas candidatas para COVID-19, en el que destacaba las ocho de ellas ya est\u00e1n en fase de evaluaci\u00f3n cl\u00ednica. A continuaci\u00f3n, presentamos estas ocho que ya est\u00e1n siendo probadas en personas.\nVacunas en evaluaci\u00f3n cl\u00ednica:\n|Nombre||Tipo de vacuna||Desarrollador||Estado actual de la evaluaci\u00f3n cl\u00ednica|\n|Ad5-nCoV||Vector viral no replicativo||CanSino Biologics Inc./Beijing Institute of Biotechnology||\nFase 2\n|\nChiCTR2000031781\nFase 1\nChiCTR2000030906\nFase1\nNCT0431312127\nFase 2\nNCT04341389\n|mRNA-1273||ARN||Moderna/NIAID||\nFase 2\n|\n(IND accepted)\nFase 1\nNCT04283461\n|Virus Inactivado||Wuhan Institute of Biological Products/Sinopharm||\nFase 1/2\n|\nChiCTR2000031809\n|Virus Inactivado||Beijing Institute of Biological Products/Sinopharm||Fase 1/2 ChiCTR2000032459|\n|PiCoVacc||Virus Inactivado||Sinovac||\nFase 1/2\n|\nNCT04352608\n|ChAdOx1 nCoV-19||Vector viral no replicativo||University of Oxford||\nFase 1/2\n|\nNCT04324606\n|BNT162a1, BNT162b1, BNT162b2 y BNT162c2||ARN||BioNTech/Fosun Pharma/Pfizer||Fase 1/2 2020-001038-36 NCT04368728|\n|INO-4800||ADN||Inovio Pharmaceuticals||\nFase 1\n|\nNCT04336410\nLa vacuna Ad5-nCoV de la biotecnol\u00f3gica china CanSino Biological ha sido la primera vacuna frente al coronavirus en ser evaluada en un ensayo en fase 2. Esta vacuna se basa en utilizar vectores virales que han perdido su capacidad replicativa para hacer llegar las instrucciones de la prote\u00edna S del virus al interior de las c\u00e9lulas.La prote\u00edna S tiene un papel cr\u00edtico en la infecci\u00f3n, ya que es la que interacciona con prote\u00ednas espec\u00edficas de la superficie de las c\u00e9lulas e induce la entrada del virus a las mismas. La administraci\u00f3n de Ad5-nCoV lleva a que las c\u00e9lulas tratadas produzcan la prote\u00edna viral, cuya presencia provoca una respuesta por parte del sistema inmunitario y lo prepara para una posible infecci\u00f3n real por el coronavirus SARS-CoV-2.\nLa fase 2 del estudio cl\u00ednico, en la que se espera reclutar a 500 participantes, evaluar\u00e1 la seguridad y capacidad inmunog\u00e9nica de la vacuna.\nPara desarrollar Ad5-nCoV, CanSino Biologics Inc ha utilizado la misma plataforma de vacunas basadas en vectores virales basados en adenovirus que utiliz\u00f3 con \u00e9xito para el dise\u00f1o de una vacuna frente al virus del \u00c9bola.\nLa vacuna basada en ARN mensajero desarrollada por Moderna, es sin duda, una de las vacunas m\u00e1s prometedoras. Esta vacuna est\u00e1 compuesta por nanopart\u00edculas lip\u00eddicas que contienen ARN con la informaci\u00f3n necesaria para producir una forma estable de la prote\u00edna S viral. Su objetivo es hacer llegar el ARN mensajero al interior de las c\u00e9lulas del organismo para que \u00e9stas sinteticen la prote\u00edna y se genere una respuesta inmunitaria que lleve a la generaci\u00f3n de inmunidad de la persona.\nLos resultados preliminares del\n[primer ensayo](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine) en 45 personas sanas con esta vacuna son positivos. Sus responsables indican que en general la vacuna es tolerada por los participantes voluntarios y muestra unos niveles de seguridad adecuados. Adem\u00e1s, se\u00f1alan que los datos disponibles son consistentes con una producci\u00f3n de anticuerpos similar a la de observada en sangre de pacientes recuperados de COVID-19. De momento, los resultados corresponden a pocas personas y [se desconoce](https://www.statnews.com/2020/05/19/vaccine-experts-say-moderna-didnt-produce-data-critical-to-assessing-covid-19-vaccine/) si la respuesta es duradera, por lo que ser\u00e1 necesario seguir investigando. La siguiente fase del ensayo, en la que se probar\u00e1 la vacuna en 600 personas ha sido ya aprobada y, si todo evoluciona correctamente, se espera empezar la fase 3 en julio.\nEl Instituto de Productos Biol\u00f3gicos de Wuhan, subsidiaria de la empresa Sinopharm, est\u00e1 desarrollando una vacuna basada en virus inactivados obtenidos de c\u00e9lulas Vero. Esta l\u00ednea celular, derivada de c\u00e9lulas epiteliales de ri\u00f1\u00f3n de mono, ya se ha utilizado desarrollar vacunas para otros virus como el de la rabia o el de la gripe.\nLos virus inactivados pueden funcionar como vacunas debido a que su presencia genera la misma respuesta que una infecci\u00f3n habitual. Inducen la acci\u00f3n del sistema inmunitario pero, al no ser capaces de reproducirse, no causan el mismo da\u00f1o que el virus intacto.\nUna segunda vacuna de Sinopharm est\u00e1 en desarrollo en colaboraci\u00f3n con el Instituto de de Beijing de Productos Biol\u00f3gicos y el Centro Chino de Control y Prevenci\u00f3n de Enfermedades.\nEl pasado 17 de abril la empresa china Sinovac Biotech\n[informaba](http://www.sinovac.com/?optionid=754&auto_id=897) del inicio de un ensayo cl\u00ednico en fase 1 para evaluar su vacuna candidata frente a COVID-19. La vacuna consiste tambi\u00e9n en virus inactivados purificados de c\u00e9lulas Vero y ha mostrado efectividad en diferentes modelos animales. Adem\u00e1s de los virus inactivados se a\u00f1ade un activador del sistema inmunitario, un gel compuesto de fosfato de aluminio o hidr\u00f3xido de aluminio, llamado alum.\nUn reciente art\u00edculo en\n[Science](https://science.sciencemag.org/content/early/2020/05/06/science.abc1932) describe el desarrollo de la vacuna y los primeros resultados obtenidos en modelos en rata, rat\u00f3n y primates no humanos.\nEl Instituto Jenner de la Universidad de Oxford, en colaboraci\u00f3n con el Grupo de Vacunas de Oxford, ha desarrollado la vacuna ChAdOx1 nCoV-19 que utiliza un vector viral no replicativo para introducir las instrucciones de la prote\u00edna S del coronavirus en las c\u00e9lulas humanas. El ensayo cl\u00ednico de fase I, en el que se espera que participen 1100 participantes\n[comenz\u00f3](https://www.research.ox.ac.uk/Article/2020-04-23-oxford-covid-19-vaccine-begins-human-trial-stage) a finales de abril.\nLa plataforma de desarrollo de vacunas del Instituto Jenner ha sido utilizada para desarrollar vacunas para otros virus, incluidos el MERS, el Chikungunya o el virus de la gripe. Todas estas vacunas utilizan la misma versi\u00f3n del adenovirus ChAdOx1, que habitualmente causa infecciones en chimpanc\u00e9s y ha sido modificada gen\u00e9ticamente para no ser infectiva en humanos. M\u00e1s de 320 personas han recibido este tipo de vacunas, que se consideran seguras, aunque pueden causar algunos efectos secundarios temporales.\nLa Universidad de Oxford y Vaccitech, empresa spin-off que desarrolla la vacuna,\n[anunciaron](http://www.ox.ac.uk/news/2020-04-30-landmark-partnership-announced-development-covid-19-vaccine) recientemente un acuerdo con la empresa Astra-Zeneca para el desarrollo, producci\u00f3n a gran escala y distribuci\u00f3n de la vacuna. Su objetivo es conseguir que est\u00e9 disponible lo antes posible.\nLa empresa alemana BioNTech ha desarrollado cuatro vacunas candidatas para COVID-19 basadas en ARN: BNT162a1, BNT162b1, BNT162b2 y BNT162c2.\nLas vacunas utilizan diferentes formatos de ARN mensajero que codifican para la prote\u00edna S completa o para su dominio de uni\u00f3n al receptor. Adem\u00e1s, cada formato se combina con una f\u00f3rmula de nanopart\u00edculas lip\u00eddicas.\nLos primeros participantes del ensayo cl\u00ednico en Europa recibieron dosis de la primera vacuna candidata a finales de Abril. Se espera las diferentes fases de los ensayos cl\u00ednicos de EE.UU. y Europa incluyan aproximadamente 7.600 participantes.\nPara el desarrollo, producci\u00f3n y distribuci\u00f3n mundial de las vacunas BioNTech ha\n[establecido alianzas](https://www.pfizer.es/noticia/pfizer_biontech_vacunan_primeros_participantes_estudios_clinicos_estados_unidos_parte_programa_global_desarrollo_vacunas_arnm_covid_19.html) con la farmac\u00e9utica Pfizer. Tambi\u00e9n colabora con [Fosun Pharma](https://www.fosunpharma.com/en/news/news-details-3801.html) en el desarrollo cl\u00ednico y comercializaci\u00f3n de su programa vacunal en China.\nLa empresa estadounidense Inovio completa el panel de vacunas para COVID-19 que ya se est\u00e1n probando en personas en ensayos cl\u00ednicos. En su p\u00e1gina web\n[Inovio](https://www.inovio.com/our-focus-serving-patients/covid-19/) se\u00f1ala que dise\u00f1\u00f3 su vacuna de ADN INO-4800 en tres horas, tras recibir la informaci\u00f3n del genoma del virus.\nINO-4800 es una vacuna de ADN que se administra mediante una inyecci\u00f3n intrad\u00e9rmica seguida de un tratamiento de electroporaci\u00f3n que crea poros en las membranas de las c\u00e9lulas y permite que el ADN acceda a su interior. El ADN consiste en un pl\u00e1smido, una mol\u00e9cula de ADN circular, que contiene la informaci\u00f3n necesaria para producir la prote\u00edna S viral. En este caso, a diferencia de las vacunas de ARN que pueden ser traducidas directamente a prote\u00edna, es necesario que el ADN se transcriba a ARN mensajero en el interior de las c\u00e9lulas.\nEl primer ensayo cl\u00ednico para probar INO-4800 comenz\u00f3 a principios de abril en Estados Unidos, donde se incluyeron 40 voluntarios sanos. Est\u00e1n previstos ensayos cl\u00ednicos tambi\u00e9n en China y Korea del Sur.\nLa empresa conf\u00eda en completar los estudios cl\u00ednicos en oto\u00f1o y planea producir 1 mill\u00f3n de dosis a finales de a\u00f1o, para continuar los ensayos cl\u00ednicos o ser utilizadas como medida de emergencia.\nConocidas cu\u00e1les son las vacunas que ya se est\u00e1n probando en ensayos cl\u00ednicos, la siguiente pregunta es para cu\u00e1ndo se estima que podr\u00eda existir una vacuna disponible para su utilizaci\u00f3n cl\u00ednica. En este punto hay que considerar que, aunque disponer de 8 vacunas candidatas para COVID-19 en fase cl\u00ednica sea muy prometedor, no todas las candidatas que consiguen aprobaci\u00f3n para un ensayo en fase 1 avanzan hasta fase 3 o llegan a convertirse en vacunas comerciales.\nEl desarrollo de vacunas es lento. Suele requerir m\u00e1s de 5 a\u00f1os, e incluso en algunos casos, d\u00e9cadas. No obstante, dada la situaci\u00f3n de emergencia actual, se est\u00e1n acelerando todos los plazos para conseguir obtener una vacuna eficaz y segura en el menor tiempo posible. En estas circunstancias, podr\u00eda haber una reducci\u00f3n en el tiempo de desarrollo y obtenerse una entre 12 y 18 meses. Pero no es seguro. Adem\u00e1s, hay que considerar no solo la etapa de dise\u00f1o y evaluaci\u00f3n de la vacuna, sino la capacidad para producirla y distribuirla a gran escala, por lo que es dif\u00edcil calcular una fecha aproximada.\nTonia Thomas, del Grupo de Vacunas de la Universidad de Oxford,\n[indica](https://covid19vaccinetrial.co.uk/blog-how-long-will-it-take-get-oxford-vaccine-deployment) que en el escenario m\u00e1s propicio, esperan conseguir resultados positivos del ensayo cl\u00ednico de fase III de su vacuna ChAdOx1 nCoV-19 y capacidad para fabricar grandes cantidades en oto\u00f1o. Sin embargo, destaca que esta estimaci\u00f3n es muy ambiciosa y podr\u00eda estar sujeta a cambios.\nUn plazo similar es el que estima Inovio. Si su vacuna se muestra efectiva y segura, y obtienen financiaci\u00f3n, planean producir 1 mill\u00f3n de dosis para finales de a\u00f1o.\nTodo indica que cualquier vacuna para COVID-19 tardar\u00e1 meses en llegar. E incluso una vez, exista, habr\u00e1 que gestionar su producci\u00f3n y distribuci\u00f3n a gran escala. Este \u00faltimo factor puede ser muy relevante en el caso de aquellos laboratorios que no tienen capacidad para producir grandes cantidades.\nOtra cuesti\u00f3n importante ser\u00e1 asegurar que la vacuna pueda llegar a todos los que la necesiten. Al tratarse de una enfermedad que afecta a mundial, a las pol\u00edticas propias de cada pa\u00eds se a\u00f1ade la posible competici\u00f3n por conseguir la vacuna entre pa\u00edses. En este contexto ser\u00e1 todav\u00eda m\u00e1s necesaria una gesti\u00f3n adecuada.", "language": null, "image": null, "pagetype": null, "links": ["http://biotech-spain.com/en/", null, "http://biotech-spain.com/en/", "http://biotech-spain.com/en/articles", "http://biotech-spain.com/en/directory", "http://biotech-spain.com/en/admin/", "http://biotech-spain.com/en/contact", "/en", "/es", "https://www.facebook.com/biotech.in.spain", "https://twitter.com/Biotech_Spain", "https://plus.google.com/+Biotechspain-Biotecnolog\u00eda-en-Espa\u00f1a", "https://www.linkedin.com/company/biotech-spain/", "http://biotech-spain.com/en/", "http://biotech-spain.com/en/articles", "http://biotech-spain.com/en/articles?category=vaccines", "http://biotech-spain.com/en/articles?category=research-services-and-supp", "http://biotech-spain.com/en/articles?category=research-network", "http://biotech-spain.com/en/articles?category=proteomics", "http://biotech-spain.com/en/articles?category=proteins", "http://biotech-spain.com/en/articles?category=othe", "http://biotech-spain.com/en/articles?category=immunology", "http://biotech-spain.com/en/articles?category=infections", "http://biotech-spain.com/en/articles?category=epidemiology", "http://biotech-spain.com/en/articles?category=clinical-trials", "http://biotech-spain.com/en/articles?category=research-centers", "http://biotech-spain.com/en/articles?category=cellular-and-molecular-b", "http://biotech-spain.com/en/articles/las-8-vacunas-candidatas-para-covid-19-que-ya-se-est-n-probando-en-personas/", "https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines", "https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine", "https://www.statnews.com/2020/05/19/vaccine-experts-say-moderna-didnt-produce-data-critical-to-assessing-covid-19-vaccine/", "http://www.sinovac.com/?optionid=754&auto_id=897", "https://science.sciencemag.org/content/early/2020/05/06/science.abc1932", "https://www.research.ox.ac.uk/Article/2020-04-23-oxford-covid-19-vaccine-begins-human-trial-stage", "http://www.ox.ac.uk/news/2020-04-30-landmark-partnership-announced-development-covid-19-vaccine", "https://www.pfizer.es/noticia/pfizer_biontech_vacunan_primeros_participantes_estudios_clinicos_estados_unidos_parte_programa_global_desarrollo_vacunas_arnm_covid_19.html", "https://www.fosunpharma.com/en/news/news-details-3801.html", "https://www.inovio.com/our-focus-serving-patients/covid-19/", "https://covid19vaccinetrial.co.uk/blog-how-long-will-it-take-get-oxford-vaccine-deployment", "http://biotech-spain.com/en/directory/revista+gen%c3%a9tica+m%c3%a9dica/", "http://biotech-spain.com/en/articles/tags/vacunas", "http://biotech-spain.com/en/articles/tags/covid-19", "http://biotech-spain.com/en/articles/tags/inovio", "http://biotech-spain.com/en/articles/tags/biontech", "http://biotech-spain.com/en/articles/tags/pfizer", "http://biotech-spain.com/en/articles/tags/fosun+pharma", "http://biotech-spain.com/en/articles/tags/cansino+biological", "http://biotech-spain.com/en/articles/tags/moderna", "http://biotech-spain.com/en/articles/tags/sinovac", "http://biotech-spain.com/en/articles/tags/sinopharm", "https://genotipia.com/genetica_medica_news/vacunas-covid-19/", "http://biotech-spain.com/en/admin/login", "http://biotech-spain.com/en/admin/login", "http://biotech-spain.com/en/articles/el-diagn-stico-gen-tico-neonatal-mejora-la-esperanza-de-vida-de-ni-os-con-una-inmunodeficiencia-letal/", "http://biotech-spain.com/en/articles/m-s-de-1-500-cambios-epigen-ticos-en-el-esperma-asociados-a-la-edad-paterna/", "http://biotech-spain.com/en/articles/tuneable-reverse-photochromes-in-the-solid-state-/", "#tab-1", "#tab-2", "http://biotech-spain.com/en/articles/eosin-filos-qu-significa-tener-valores-altos-o-bajos-/", "http://biotech-spain.com/en/articles/tiny-sea-creatures-reveal-the-ancient-origins-of-neurons/", "http://biotech-spain.com/en/articles/tiny-sea-creatures-reveal-the-ancient-origins-of-neurons/", "http://biotech-spain.com/en/articles/los-pacientes-con-psoriasis-grave-tienen-mayor-riesgo-cardiovascular/", "http://biotech-spain.com/en/articles/las-pruebas-moleculares-permiten-detectar-de-forma-m-s-eficaz-el-c-ncer-de-endometrio-y-evitar-histerectom-as-innecesarias-en-mujeres-con-sangrado-post-menop-usico/", "http://biotech-spain.com/en/articles/a-study-by-ibs-granada-reveals-that-exposure-to-perfluorinated-compounds-pfas-affects-the-reproductive-health-of-adolescents/", "http://biotech-spain.com/en/articles/key-protein-identified-in-fat-function-and-obesity-related-problems/", "http://biotech-spain.com/en/articles/incliva-y-uv-investigan-la-p-rdida-de-conectividad-entre-el-hipocampo-izquierdo-y-derecho-en-la-enfermedad-de-alzheimer/", "http://biotech-spain.com/en/articles/vhio-led-retrospective-study-evaluates-the-clinical-and-genomic-features-of-early-onset-pancreatic-cancer-/", "http://biotech-spain.com/en/articles/a-portable-sensor-could-detect-cancerous-tumors/", "http://biotech-spain.com/en/articles/tags/cancer", "http://biotech-spain.com/en/articles/tags/covid-19", "http://biotech-spain.com/en/articles/tags/alzheimer", "http://biotech-spain.com/en/articles/tags/investigaci%c3%b3n", "http://biotech-spain.com/en/articles/tags/salud", "http://biotech-spain.com/en/articles/tags/coronavirus", "http://biotech-spain.com/en/articles/tags/covid19", "http://biotech-spain.com/en/terms", "http://biotech-spain.com/en/privacy", "https://www.facebook.com/biotech.in.spain", "https://twitter.com/Biotech_Spain", "https://plus.google.com/+Biotechspain-Biotecnolog\u00eda-en-Espa\u00f1a", "https://www.linkedin.com/company/biotech-spain/", "http://biotech-spain.com/en/articles?category=substance-abuse", "http://biotech-spain.com/en/articles?category=agrobiotechnology", "http://biotech-spain.com/en/articles?category=food-sub", "http://biotech-spain.com/en/articles?category=animal-food-feed", "http://biotech-spain.com/en/articles?category=functional-food", "http://biotech-spain.com/en/articles?category=analgesia-pain", "http://biotech-spain.com/en/articles?category=associations", "http://biotech-spain.com/en/articles?category=biobanks", "http://biotech-spain.com/en/articles?category=bioclusters", "http://biotech-spain.com/en/articles?category=biofuels", "http://biotech-spain.com/en/articles?category=biodrugs", "http://biotech-spain.com/en/articles?category=bioinformatics", "http://biotech-spain.com/en/articles?category=cellular-and-molecular-b", "http://biotech-spain.com/en/articles?category=systems-biology", "http://biotech-spain.com/en/articles?category=evolutionary-biology", "http://biotech-spain.com/en/articles?category=synthetic-biology", "http://biotech-spain.com/en/articles?category=biomarkers", "http://biotech-spain.com/en/articles?category=biomaterials", "http://biotech-spain.com/en/articles?category=marine-based-biotechnology", "http://biotech-spain.com/en/articles?category=business-angels", "http://biotech-spain.com/en/articles?category=cancer", "http://biotech-spain.com/en/articles?category=stem-cells", "http://biotech-spain.com/en/articles?category=cardiovascular-and-cir", "http://biotech-spain.com/en/articles?category=research-centers", "http://biotech-spain.com/en/articles?category=private-clinic", "http://biotech-spain.com/en/articles?category=communication-media", "http://biotech-spain.com/en/articles?category=consultancy", "http://biotech-spain.com/en/articles?category=biologic-control-plagues-", "http://biotech-spain.com/en/articles?category=quality-control", "http://biotech-spain.com/en/articles?category=corporate-investor", "http://biotech-spain.com/en/articles?category=cosmetics", "http://biotech-spain.com/en/articles?category=cell-culture", "http://biotech-spain.com/en/articles?category=gm-crops", "http://biotech-spain.com/en/articles?category=biological-defense", "http://biotech-spain.com/en/articles?category=dental", "http://biotech-spain.com/en/articles?category=dermatology", "http://biotech-spain.com/en/articles?category=muskuloskeletal", "http://biotech-spain.com/en/articles?category=biotechnology-kits", "http://biotech-spain.com/en/articles?category=software-development", "http://biotech-spain.com/en/articles?category=diagnostic-imaging", "http://biotech-spain.com/en/articles?category=medical-devices", "http://biotech-spain.com/en/articles?category=drug-delivery", "http://biotech-spain.com/en/articles?category=drug-development", "http://biotech-spain.com/en/articles?category=drug-discovery", "http://biotech-spain.com/en/articles?category=pregnancy-reproduction", "http://biotech-spain.com/en/articles?category=venture-capital-manageme", "http://biotech-spain.com/en/articles?category=energy", "http://biotech-spain.com/en/articles?category=bone-diseases", "http://biotech-spain.com/en/articles?category=chronic-diseases", "http://biotech-spain.com/en/articles?category=degenerative-diseases", "http://biotech-spain.com/en/articles?category=genetic-diseases", "http://biotech-spain.com/en/articles?category=hereditary-diseases", "http://biotech-spain.com/en/articles?category=inflamatory-diseases", "http://biotech-spain.com/en/articles?category=neurologic-diseases", "http://biotech-spain.com/en/articles?category=rares-diseases", "http://biotech-spain.com/en/articles?category=clinical-trials", "http://biotech-spain.com/en/articles?category=public-entity", "http://biotech-spain.com/en/articles?category=epidemiology", "http://biotech-spain.com/en/articles?category=epigenetics", "http://biotech-spain.com/en/articles?category=medical-and-surgica", "http://biotech-spain.com/en/articles?category=patient-monito", "http://biotech-spain.com/en/articles?category=manufacture-of-biotech", "http://biotech-spain.com/en/articles?category=manufacter-of-resins-to-purifi", "http://biotech-spain.com/en/articles?category=manufacture-and-commercialization-of-fermentation-or-biocatalysis", "http://biotech-spain.com/en/articles?category=manufacture-and-commercialization-of-enzymes-", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=manufacture-o", "http://biotech-spain.com/en/articles?category=manufa", "http://biotech-spain.com/en/articles?category=pharmacy", "http://biotech-spain.com/en/articles?category=pharmacogenomics", "http://biotech-spain.com/en/articles?category=public-financing", "http://biotech-spain.com/en/articles?category=investment-funds", "http://biotech-spain.com/en/articles?category=training", "http://biotech-spain.com/en/articles?category=foundatio", "http://biotech-spain.com/en/articles?category=foundation", "http://biotech-spain.com/en/articles?category=genomics", "http://biotech-spain.com/en/articles?category=hospitals", "http://biotech-spain.com/en/articles?category=infections", "http://biotech-spain.com/en/articles?category=engineering", "http://biotech-spain.com/en/articles?category=immunology", "http://biotech-spain.com/en/articles?category=healthcare-facilities-and", "http://biotech-spain.com/en/articles?category=scientific-t", "http://biotech-spain.com/en/articles?category=inter", "http://biotech-spain.com/en/articles?category=institutional-investor", "http://biotech-spain.com/en/articles?category=private-investor", "http://biotech-spain.com/en/articles?category=leasing", "http://biotech-spain.com/en/articles?category=environmental-cleanup-testing", "http://biotech-spain.com/en/articles?category=maintenance-cell-culture", "http://biotech-spain.com/en/articles?category=sales-marketing", "http://biotech-spain.com/en/articles?category=environment", "http://biotech-spain.com/en/articles?category=metabolomics", "http://biotech-spain.com/en/articles?category=microbiology", "http://biotech-spain.com/en/articles?category=nanotechnology", "http://biotech-spain.com/en/articles?category=neuroscience", "http://biotech-spain.com/en/articles?category=nutrition", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=oftalmology", "http://biotech-spain.com/en/articles?category=cost-optimization", "http://biotech-spain.com/en/articles?category=othe", "http://biotech-spain.com/en/articles?category=peptides", "http://biotech-spain.com/en/articles?category=science-tec", "http://biotech-spain.com/en/articles?category=probiotics", "http://biotech-spain.com/en/articles?category=blood-products", "http://biotech-spain.com/en/articles?category=disposable-medical-prod", "http://biotech-spain.com/en/articles?category=industrial-property-p", "http://biotech-spain.com/en/articles?category=proteins", "http://biotech-spain.com/en/articles?category=proteomics", "http://biotech-spain.com/en/articles?category=dna-tests", "http://biotech-spain.com/en/articles?category=diagnostic-tests", "http://biotech-spain.com/en/articles?category=scientific-publications", "http://biotech-spain.com/en/articles?category=chemistry", "http://biotech-spain.com/en/articles?category=human-resources", "http://biotech-spain.com/en/articles?category=research-network", "http://biotech-spain.com/en/articles?category=r", "http://biotech-spain.com/en/articles?category=animal-health", "http://biotech-spain.com/en/articles?category=women-s-health", "http://biotech-spain.com/en/articles?category=child-health", "http://biotech-spain.com/en/articles?category=mental-health", "http://biotech-spain.com/en/articles?category=senior-health", "http://biotech-spain.com/en/articles?category=healthy", "http://biotech-spain.com/en/articles?category=blood-and-lymphatic-system", "http://biotech-spain.com/en/articles?category=screening", "http://biotech-spain.com/en/articles?category=food-safety", "http://biotech-spain.com/en/articles?category=cro-cmo-services", "http://biotech-spain.com/en/articles?category=research-services-and-supp", "http://biotech-spain.com/en/articles?category=legal-services", "http://biotech-spain.com/en/articles?category=auditory-system", "http://biotech-spain.com/en/articles?category=digestive-system", "http://biotech-spain.com/en/articles?category=kidney-and-geni", "http://biotech-spain.com/en/articles?category=locomotive-system", "http://biotech-spain.com/en/articles?category=metabolic-sy", "http://biotech-spain.com/en/articles?category=central-nervous-system", "http://biotech-spain.com/en/articles?category=respiratory-and-pulmonary-sy", "http://biotech-spain.com/en/articles?category=laser-optical-systems", "http://biotech-spain.com/en/articles?category=cellular-therapy", "http://biotech-spain.com/en/articles?category=gene-therapy", "http://biotech-spain.com/en/articles?category=tissue-therapy", "http://biotech-spain.com/en/articles?category=toxicology", "http://biotech-spain.com/en/articles?category=technology-transfer", "http://biotech-spain.com/en/articles?category=transplant", "http://biotech-spain.com/en/articles?category=universities", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=vaccines", "http://biotech-spain.com/en/articles?category=", "http://biotech-spain.com/en/articles?category=venture-capital", "http://biotech-spain.com/en/articles?category=vitamins-and-nutri", "http://biotech-spain.com/en/articles?category=viral-vector", "http://biotech-spain.com/en/directory?category=substance-abuse", "http://biotech-spain.com/en/directory?category=agrobiotechnology", "http://biotech-spain.com/en/directory?category=food-sub", "http://biotech-spain.com/en/directory?category=animal-food-feed", "http://biotech-spain.com/en/directory?category=functional-food", "http://biotech-spain.com/en/directory?category=analgesia-pain", "http://biotech-spain.com/en/directory?category=associations", "http://biotech-spain.com/en/directory?category=biobanks", "http://biotech-spain.com/en/directory?category=bioclusters", "http://biotech-spain.com/en/directory?category=biofuels", "http://biotech-spain.com/en/directory?category=biodrugs", "http://biotech-spain.com/en/directory?category=bioinformatics", "http://biotech-spain.com/en/directory?category=cellular-and-molecular-b", "http://biotech-spain.com/en/directory?category=systems-biology", "http://biotech-spain.com/en/directory?category=evolutionary-biology", "http://biotech-spain.com/en/directory?category=synthetic-biology", "http://biotech-spain.com/en/directory?category=biomarkers", "http://biotech-spain.com/en/directory?category=biomaterials", "http://biotech-spain.com/en/directory?category=marine-based-biotechnology", "http://biotech-spain.com/en/directory?category=business-angels", "http://biotech-spain.com/en/directory?category=cancer", "http://biotech-spain.com/en/directory?category=stem-cells", "http://biotech-spain.com/en/directory?category=cardiovascular-and-cir", "http://biotech-spain.com/en/directory?category=research-centers", "http://biotech-spain.com/en/directory?category=private-clinic", "http://biotech-spain.com/en/directory?category=communication-media", "http://biotech-spain.com/en/directory?category=consultancy", "http://biotech-spain.com/en/directory?category=biologic-control-plagues-", "http://biotech-spain.com/en/directory?category=quality-control", "http://biotech-spain.com/en/directory?category=corporate-investor", "http://biotech-spain.com/en/directory?category=cosmetics", "http://biotech-spain.com/en/directory?category=cell-culture", "http://biotech-spain.com/en/directory?category=gm-crops", "http://biotech-spain.com/en/directory?category=biological-defense", "http://biotech-spain.com/en/directory?category=dental", "http://biotech-spain.com/en/directory?category=dermatology", "http://biotech-spain.com/en/directory?category=muskuloskeletal", "http://biotech-spain.com/en/directory?category=biotechnology-kits", "http://biotech-spain.com/en/directory?category=software-development", "http://biotech-spain.com/en/directory?category=diagnostic-imaging", "http://biotech-spain.com/en/directory?category=medical-devices", "http://biotech-spain.com/en/directory?category=drug-delivery", "http://biotech-spain.com/en/directory?category=drug-development", "http://biotech-spain.com/en/directory?category=drug-discovery", "http://biotech-spain.com/en/directory?category=pregnancy-reproduction", "http://biotech-spain.com/en/directory?category=venture-capital-manageme", "http://biotech-spain.com/en/directory?category=energy", "http://biotech-spain.com/en/directory?category=bone-diseases", "http://biotech-spain.com/en/directory?category=chronic-diseases", "http://biotech-spain.com/en/directory?category=degenerative-diseases", "http://biotech-spain.com/en/directory?category=genetic-diseases", "http://biotech-spain.com/en/directory?category=hereditary-diseases", "http://biotech-spain.com/en/directory?category=inflamatory-diseases", "http://biotech-spain.com/en/directory?category=neurologic-diseases", "http://biotech-spain.com/en/directory?category=rares-diseases", "http://biotech-spain.com/en/directory?category=clinical-trials", "http://biotech-spain.com/en/directory?category=public-entity", "http://biotech-spain.com/en/directory?category=epidemiology", "http://biotech-spain.com/en/directory?category=epigenetics", "http://biotech-spain.com/en/directory?category=medical-and-surgica", "http://biotech-spain.com/en/directory?category=patient-monito", "http://biotech-spain.com/en/directory?category=manufacture-of-biotech", "http://biotech-spain.com/en/directory?category=manufacter-of-resins-to-purifi", "http://biotech-spain.com/en/directory?category=manufacture-and-commercialization-of-fermentation-or-biocatalysis", "http://biotech-spain.com/en/directory?category=manufacture-and-commercialization-of-enzymes-", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=manufacture-o", "http://biotech-spain.com/en/directory?category=manufa", "http://biotech-spain.com/en/directory?category=pharmacy", "http://biotech-spain.com/en/directory?category=pharmacogenomics", "http://biotech-spain.com/en/directory?category=public-financing", "http://biotech-spain.com/en/directory?category=investment-funds", "http://biotech-spain.com/en/directory?category=training", "http://biotech-spain.com/en/directory?category=foundatio", "http://biotech-spain.com/en/directory?category=foundation", "http://biotech-spain.com/en/directory?category=genomics", "http://biotech-spain.com/en/directory?category=hospitals", "http://biotech-spain.com/en/directory?category=infections", "http://biotech-spain.com/en/directory?category=engineering", "http://biotech-spain.com/en/directory?category=immunology", "http://biotech-spain.com/en/directory?category=healthcare-facilities-and", "http://biotech-spain.com/en/directory?category=scientific-t", "http://biotech-spain.com/en/directory?category=inter", "http://biotech-spain.com/en/directory?category=institutional-investor", "http://biotech-spain.com/en/directory?category=private-investor", "http://biotech-spain.com/en/directory?category=leasing", "http://biotech-spain.com/en/directory?category=environmental-cleanup-testing", "http://biotech-spain.com/en/directory?category=maintenance-cell-culture", "http://biotech-spain.com/en/directory?category=sales-marketing", "http://biotech-spain.com/en/directory?category=environment", "http://biotech-spain.com/en/directory?category=metabolomics", "http://biotech-spain.com/en/directory?category=microbiology", "http://biotech-spain.com/en/directory?category=nanotechnology", "http://biotech-spain.com/en/directory?category=neuroscience", "http://biotech-spain.com/en/directory?category=nutrition", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=oftalmology", "http://biotech-spain.com/en/directory?category=cost-optimization", "http://biotech-spain.com/en/directory?category=othe", "http://biotech-spain.com/en/directory?category=peptides", "http://biotech-spain.com/en/directory?category=science-tec", "http://biotech-spain.com/en/directory?category=probiotics", "http://biotech-spain.com/en/directory?category=blood-products", "http://biotech-spain.com/en/directory?category=disposable-medical-prod", "http://biotech-spain.com/en/directory?category=industrial-property-p", "http://biotech-spain.com/en/directory?category=proteins", "http://biotech-spain.com/en/directory?category=proteomics", "http://biotech-spain.com/en/directory?category=dna-tests", "http://biotech-spain.com/en/directory?category=diagnostic-tests", "http://biotech-spain.com/en/directory?category=scientific-publications", "http://biotech-spain.com/en/directory?category=chemistry", "http://biotech-spain.com/en/directory?category=human-resources", "http://biotech-spain.com/en/directory?category=research-network", "http://biotech-spain.com/en/directory?category=r", "http://biotech-spain.com/en/directory?category=animal-health", "http://biotech-spain.com/en/directory?category=women-s-health", "http://biotech-spain.com/en/directory?category=child-health", "http://biotech-spain.com/en/directory?category=mental-health", "http://biotech-spain.com/en/directory?category=senior-health", "http://biotech-spain.com/en/directory?category=healthy", "http://biotech-spain.com/en/directory?category=blood-and-lymphatic-system", "http://biotech-spain.com/en/directory?category=screening", "http://biotech-spain.com/en/directory?category=food-safety", "http://biotech-spain.com/en/directory?category=cro-cmo-services", "http://biotech-spain.com/en/directory?category=research-services-and-supp", "http://biotech-spain.com/en/directory?category=legal-services", "http://biotech-spain.com/en/directory?category=auditory-system", "http://biotech-spain.com/en/directory?category=digestive-system", "http://biotech-spain.com/en/directory?category=kidney-and-geni", "http://biotech-spain.com/en/directory?category=locomotive-system", "http://biotech-spain.com/en/directory?category=metabolic-sy", "http://biotech-spain.com/en/directory?category=central-nervous-system", "http://biotech-spain.com/en/directory?category=respiratory-and-pulmonary-sy", "http://biotech-spain.com/en/directory?category=laser-optical-systems", "http://biotech-spain.com/en/directory?category=cellular-therapy", "http://biotech-spain.com/en/directory?category=gene-therapy", "http://biotech-spain.com/en/directory?category=tissue-therapy", "http://biotech-spain.com/en/directory?category=toxicology", "http://biotech-spain.com/en/directory?category=technology-transfer", "http://biotech-spain.com/en/directory?category=transplant", "http://biotech-spain.com/en/directory?category=universities", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=vaccines", "http://biotech-spain.com/en/directory?category=", "http://biotech-spain.com/en/directory?category=venture-capital", "http://biotech-spain.com/en/directory?category=vitamins-and-nutri", "http://biotech-spain.com/en/directory?category=viral-vector"]}